When a company beats Wall Street's profit estimates and raises its outlook, yet the stock still drops, it often means the selling is driven by short-term disappointment rather than fundamental deterioration. Cigna actually improved its guidance, suggestin

Verdict: wait — the thesis has Cigna support but the rules are broken and Crocs is losing money

The thesis that post-earnings emotional selling creates a buyable disconnect has real teeth for Cigna: 11.2% revenue growth to $274.9B, an 83% jump in diluted EPS to $22.18, raised guidance per the Barron's piece, and a 14.3% ROE in the 79th percentile of Health Care peers all suggest the selloff is sentiment-driven. But the entry rules have never fired across 1,237 evaluated bars over 60 months, and the four-condition conjunction (RSI at or below 35, close below the lower Bollinger Band, a VWAP cross, and a rank-1 support touch) is too restrictive for any market to produce — the research author requested bounded optimization to relax it, but that search exceeded its time budget without delivering an alternative, so no robust setup was established. The risk-quality numbers are equally damning: the risk-parity portfolio delivered a -3.9% return with a -0.138 Sharpe and an expected max drawdown of 56.3% over the 730-day lookback, and Crocs posted a net loss of $81.2M with negative ROE and a 109.4% EPS decline year-over-year, making its inclusion as a "quality company at a temporary discount" hard to defend. Cigna's current ratio of 0.85 signals potential near-term liquidity pressure, with current liabilities of $56.3B exceeding current assets of $47.8B. This is a watch-list setup whose entry conditions are approaching for CI — RSI at 36.4 is just 1.4 points above the 35 trigger — but the fundamental deterioration at CROX and the zero-trigger history across both names argue against committing capital until conditions actually confirm. **Conviction breakdown:** Thesis support gets a modest lift from Cigna's genuine earnings-to-price disconnect but is capped by Crocs' net loss and the near-zero pair correlation (-0.0072) that means no real hedge. Trade readiness scores low because zero entries in five years of real daily bars means the rules are structurally broken, not just waiting. Risk quality is poor — the portfolio has negative expected returns and a 56.3% drawdown profile. Trigger proximity is moderate for CI (two of four conditions met, RSI near) but far for CROX. Fundamentals split: Cigna shows real growth, Crocs shows real deterioration.

Trade now

**Current state: both tickers are on the watch list, not at an entry.** The idea is looking for an oversold bounce in Cigna (CI) and Crocs (CROX) after their post-earnings selloffs, but the strategy requires four conditions to fire simultaneously and only two are live right now. **Cigna (CI) — last close $279.05.** Two of four conditions are already met: price is below the 20-period Bollinger Band ($289.97) and the stock is near its rank-1 support at $270.21. The two missing pieces: RSI (14) sits at 36.4, needing a drop to at or below 35 (just 1.4 points away), and VWAP has not been crossed to the upside. The ADX (14) at 16.5 already satisfies the eventual exit condition (below 20), confirming a low-trend environment. **Crocs (CROX) — last close $128.01.** Further from triggering. Price is below its 20-period Bollinger Band ($131.78) and the stock is near its rank-1 support at $126.04, but RSI (14) at 42.0 is 7.0 points above the 35 trigger, and VWAP has not been crossed. ADX (14) at 29.2 is well above the exit threshold of 20, meaning the trend hasn't exhausted yet. **Risk parameters if triggered:** Stop loss is fixed at a 2.5% decline from entry; take profit targets a 5.0% gain, giving an effective reward-to-risk of roughly 2:1. A separate support-based stop at rank-2 support ($264.90 for CI; $119.87 for CROX) also applies. "Wait" means do nothing today — set price and RSI alerts at the trigger levels and let the setup come to you. No robust parameter setup was established, so no adjusted threshold variant is recommended.

Real Fundamentals Behind the "Good News" Selling

The idea's core argument is that emotional selling is creating a disconnect between stock price and business performance. For Cigna, the numbers genuinely support the "good news" narrative. Revenue grew 11.2% year-over-year to $274.9B, and diluted EPS of $22.18 represents an 83% jump from the prior year. Per the Barron's piece on the earnings reaction, management actually raised guidance — a concrete signal that the business trajectory is improving, not deteriorating. The thesis that the selloff is driven by short-term disappointment rather than fundamental weakness finds real support in Cigna's top-line momentum and management's own forward confidence. Crocs presents a more mixed but still defensible case for the bull thesis. The company…

Scores

• Conviction score breakdown: 34
• Thesis support: 45
• Trade readiness: 15
• Risk quality: 20
• Trigger proximity: 48
• Fundamentals trend: 42

Watch items

• CI — RSI (14)
• CI — Price vs Bollinger Band (20)
• CI — Rank-1 Support Touch
• CI — VWAP Cross
• CI — Rank-2 Support Break
• CROX — RSI (14)
• CROX — Price vs Bollinger Band (20)
• CROX — Rank-1 Support Touch
• CROX — VWAP Cross
• CROX — Rank-2 Support Break
• CROX — ADX (14)
• CI — RSI (14) below 35
• CI — Price below Bollinger (20)